<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819386</url>
  </required_header>
  <id_info>
    <org_study_id>CASVE-NM-21-516</org_study_id>
    <nct_id>NCT04819386</nct_id>
  </id_info>
  <brief_title>NEIVATECH Virtual Reality-Based System Randomized Pilot Trial</brief_title>
  <acronym>NEIVATECH</acronym>
  <official_title>Randomized Pilot Trial of the NEIVATECH Virtual Reality-Based System to Improve Visual Function in Children With Anisometropic Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Increase-Tech</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alicante</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Increase-Tech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to pilot-test a novel VR-based system designed to provide binocular&#xD;
      vision training to anisometropic amblyopic children by complementing the concepts of&#xD;
      dichoptic training and perceptual learning with a gamification approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the worldwide impact of amblyopia, there is a medical and social need, and at the same&#xD;
      time a clear market niche, for the design and development of new systems to improve the&#xD;
      efficacy rates of conventional treatments such as occlusion or penalisation therapies.&#xD;
&#xD;
      In this context, the final objective of the NEIVATECH project is to pilot test a new system&#xD;
      that integrates Virtual Reality hardware and software technologies for binocular visual&#xD;
      training in anisometropic amblyopic children, combining perceptual learning and dichoptic&#xD;
      stimuli with a gamification approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance best-corrected visual acuity (BCVA)</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>ETDRS, logMAR scale, maximum -0.3 (best) and minimum 1.20 (worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Near BCVA</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>ETDRS, logMAR scale, maximum -0.3 (best) and minimum 1.20 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photopic contrast sensitivity function (CSF)</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>CSV-1000 test for spatial frequencies of 3, 6, 12 and 18 cycles/degree</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Refraction under cycloplegia</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Magnitude of sphere and cylinder (diopters), orientation of axis of astigmatism (degrees)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stereopsis</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Magnitude of stereoacuity (seconds of arc)</description>
  </other_outcome>
  <other_outcome>
    <measure>Binocular vision</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Worth's four dot test and Four prism dioptre reflex text</description>
  </other_outcome>
  <other_outcome>
    <measure>Fusional vergence</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Magnitude of base-out and base-in prisms needed to obtain diplopia while the patient is looking at a distance and near (40 cm) stimulus</description>
  </other_outcome>
  <other_outcome>
    <measure>Accommodative facility</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Number of changes performed achieving an optimum focus using a spherical flipper of +-2.00 D while the patient is looking at a near optotype (VA 0,63)</description>
  </other_outcome>
  <other_outcome>
    <measure>Near point of convergence</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Closest distance in cm in reference to the nasal root of the patient at which the subject is able to maintain single vision</description>
  </other_outcome>
  <other_outcome>
    <measure>Oculomotor pattern</measure>
    <time_frame>Pre-intervention visit, one month visit, two-month visit and three-month visit</time_frame>
    <description>Number of regressions and corrective movements during the performance of 5 cycles of change of fixation (saccadic movements) between two stimuli separated 20 cm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anisometropic Amblyopia</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 half-hour in-office active vision therapy sessions with the NEIVATECH system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 hours of conventional patching per day at home</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NEIVATECH active vision therapy sessions</intervention_name>
    <description>NEIVATECH active vision therapy sessions will be 18 in total, will have an average duration of half an hour, and will be distributed in the following way: 5 sessions in the first week (Monday to Friday), 3 sessions in the second week (Monday, Wednesday, Friday) and 1 maintenance session in the following weeks (Wednesday). As participation in the study will last for three months, patients assigned to group A will have 10 active vision therapy sessions during the first month of treatment, 4 during the second month, and 4 during the third month.</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Occlusion therapy</intervention_name>
    <description>2 hours of conventional patching per day at home, every day for the 3 month duration of the study.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged between 5 and 17 years.&#xD;
&#xD;
          -  Willingness to perform the assigned therapy and to carry out the established visits.&#xD;
&#xD;
          -  No history of previous treatment for amblyopia other than optimal refractive&#xD;
             correction for at least 2 months prior to inclusion in the study.&#xD;
&#xD;
          -  BCVA in the amblyopic eye of ≤ 0.1 logMAR with at least 1 logMAR line difference&#xD;
             between the two eyes of the same patient.&#xD;
&#xD;
          -  Presence of anisometropia defined as a difference in spherical equivalent between the&#xD;
             two eyes of ≥ 1.5 dioptres.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active eye disease.&#xD;
&#xD;
          -  Previous ocular surgery.&#xD;
&#xD;
          -  BCVA in the amblyopic eye of ≥ 0.70 logMAR.&#xD;
&#xD;
          -  Presence of strabismic or deprivation amblyopia.&#xD;
&#xD;
          -  Presence of microtropia or intermittent strabismus.&#xD;
&#xD;
          -  Presence of irregular cornea due to astigmatism or ectatic corneal disease.&#xD;
&#xD;
          -  Presence of cognitive impairment or psychiatric or neurological disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Francisco Arenillas Lara, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Francisco Arenillas Lara, PhD</last_name>
    <phone>+34637890926</phone>
    <phone_ext>+34</phone_ext>
    <email>juanfarenillas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Begoña Coco Martín, PhD</last_name>
    <phone>607802586</phone>
    <phone_ext>+34</phone_ext>
    <email>mbegococom@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>María Begoña Coco Martín, PhD</last_name>
      <phone>607802586</phone>
      <phone_ext>+34</phone_ext>
      <email>mbegococom@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Increase-Tech</investigator_affiliation>
    <investigator_full_name>Juan Francisco Arenillas Lara</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Amblyopic children</keyword>
  <keyword>Perceptual learning</keyword>
  <keyword>Dichoptic training</keyword>
  <keyword>Gamification</keyword>
  <keyword>Virtual reality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

